Evidence map›Paper›PMID 25019921›Full record

ReviewDeutsches Arzteblatt international2014

Non-alcoholic fatty liver disease: epidemiology, clinical course, investigation, and treatment.

Johannes Weiß, Monika Rau, Andreas Geier

Registry-linked trialOpen access · greenAbstract readReview
In one paragraph

Review in Deutsches Arzteblatt international, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06757348 (Association Between Fatty Liver and Pancreatic Steatosis in Patients With Metabolic Syndrome), which is not on this map. Cited by 67 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed, 4 pooled it
10.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06757348 not yet recruitingnot on this mapstarted 2025, after this paper: background citation

Association Between Fatty Liver and Pancreatic Steatosis in Patients With Metabolic Syndrome

TypeobservationalSponsorMaria Marta PiskorzRan2025 to 2026Enrolled61ConditionsExocrine Pancreatic Insufficiency, Fatty Liver, Nonalcoholic, Pancreatic SteatosisArmsFecal elastase, Ecoendoscopy, Fibroscan, Serum cytokines
3 · Its place in the literature

Who cites it

67 citing papers in PubMed, 4 syntheses or guidelines pooled it, 154 citations in OpenAlex.

  1. Pooled it
  2. Correlation Between Adiponectin Gene rs1501299 Polymorphism and Nonalcoholic Fatty Liver Disease Susceptibility: A Systematic Review and Meta-Analysis.Medical science monitor : international medical journal of experimental and clinical research · 2019
    Pooled it
  3. Resection or Transplant in Early Hepatocellular Carcinoma.Deutsches Arzteblatt international · 2017
    Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. International journal of molecular sciences · 2023
    Article
  13. Nutrients · 2023
    Review
  14. Article
  15. Review
  16. Food & nutrition research · 2023
    Article
  17. Article
  18. Article
  19. Review
  20. Article

7 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Johannes WeißDepartment of Internal Medicine II, Division of Hepatology, University Hospital of Würzburg.
Monika Rau
Andreas Geier
Universitätsklinikum Würzburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe global obesity epidemic has increased the prevalence of fatty liver disease. At present, 14% to 27% of the general population in the industrialized world has non-alcoholic fatty liver disease (NAFLD).

methodWe review pertinent publications retrieved by a selective search of the PubMed database for the years 1995 to 2013.

resultsThe term "non-alcoholic fatty liver disease" covers cases of a wide spectrum of severity, ranging from bland fatty liver without any inflammation and with little or no tendency to progress all the way to non-alcoholic steato-hepatitis (NASH) with inflammatory reactions and hepatocyte damage, with or without fibrosis. Some 5% to 20% of patients with NAFLD develop NASH, which undergoes a further transition to higher-grade fibrosis in 10% to 20% of cases. In fewer than 5% of cases, fibrosis progresses to cirrhosis. These approximate figures lead to an estimate of 0.05% to 0.3% for the prevalence of cirrhosis in the general population. About 2% of all cirrhosis patients per year develop hepatocellular carcinoma. The diagnosis of fatty liver disease can be suspected initially on the basis of abnormally high aspartate aminotransferase (ASAT) and/or alanine aminotransferase (ALAT) levels and abnormal ultrasonographic findings. The positive predictive value of an ultrasonographic study for mild steatosis is 67% at most. The NAFLD fibrosis score, which is computed on the basis of multiple parameters (age, body-mass index, diabetes status, ASAT, ALAT, platelet count, and albumin level), has a positive predictive value of 82% to 90% and a negative predictive value of 88% to 93%. Liver biopsy is the gold standard for diagnosis but should be performed sparingly in view of its rare but sometimes life-threatening complications, such as hemorrhage. The treatment of NAFLD and NASH consists mainly of changes in lifestyle and nutrition.

conclusionNAFLD can, in principle, be reversed. This is only possible with weight reduction by at least 3% to 5%.

Indexed as

Risk Reduction BehaviorCombined Modality TherapyDiagnosis, DifferentialDiet TherapyHumansInternationalityNon-alcoholic Fatty Liver DiseasePrevalenceRisk Factors

Identifiers

PMID25019921
PMCPMC4101528
OpenAlexW1433606059

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.